Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Laboratory Medical Tests: the FDA’s Newest Regulatory Objective

Client Alert

On September 29, 2023, the Food and Drug Administration (FDA) released a proposed rule aimed at strengthening federal regulation of laboratory medical tests. Though the laboratory medical test industry has become a multibillion-dollar industry in America, the industry has never come within the FDA’s regulatory breadth. FDA Commissioner Robert Califf said the proposed rule targets laboratory medical tests that produce inaccurate results, to the risk of patient safety.

Why is the proposed rule necessary?

The risk to patients from laboratory tests has increased in recent years. In decades past, most lab-based tests were “lower risk, small volume” products used for local patients, according to the FDA. As the laboratory test market has grown exponentially, with laboratory companies processing thousands of blood and urine tests per week, there has been little quality control over these tests.

FDA officials have long highlighted the dangers of inaccurate laboratory tests for consumers. Specifically, inaccurate tests can lead to patients receiving an incorrect diagnosis, skipping necessary treatments, or receiving unnecessary medication or surgery. As more tests are mass-produced and mass-marketed, more consumers are facing unreliable and inaccurate tests, prompting the FDA to act.

However, problems with the mass-produced diagnostic test market are not uncommon. During the Coronavirus pandemic, U.S. laboratories quickly produced and sold to American consumers batches of COVID-19 tests without federal oversight. More recently, pregnancy tests produced by laboratories have been advertised to consumers with the promise that they can screen for genetic mutations that can lead to Down’s syndrome, cystic fibrosis, and other disorders. Other laboratory tests advertised directly to consumers have claimed to measure the risk of developing ailments like Alzheimer’s and autism. In response, numerous studies and reports identified that the tests misstated or exaggerated the risks of those conditions to vulnerable consumers.

This proposed rule is not the first time the FDA has attempted to regulate the laboratory industry. Over ten years ago, the FDA drafted guidelines for the industry, but they were never finalized. Last year, lawmakers in Congress with FDA support drafted a bill granting the FDA explicit authority to regulate high-risk tests, but the measure failed to pass in either chamber amidst opposition by industry lobbyists.

What does the proposed rule accomplish?

The FDA’s proposed rule would formally bring under FDA oversight thousands of tests performed in large laboratories. The laboratory tests specifically targeted by the FDA are developed by high-volume laboratories, including academic medical centers and large diagnostic companies. The tests can diagnose diseases like cancer, high cholesterol, and sexually transmitted infections.

Currently, the Centers for Medicare & Medicaid Services (CMS), the federal agency responsible for the Medicaid and Medicare programs, has oversight over testing laboratories. Further, inspectors evaluate the general health and safety conditions and procedures at labs, but there is no quality control or marketing standards for individual tests. Under the proposed rule, the FDA would gradually come to regulate laboratory tests over a five-year period, replacing CMS. At the end of the five years, most new tests would be subject to FDA standards and review before they could be sold to consumers.

While the laboratory industry argues that FDA regulation stifles innovation and new developments, especially during health crises, the FDA is considering exempting from review some tests already sold on the market. The FDA is now accepting comments on its proposed rule for sixty days before drafting a final rule.

If you have questions about the FDA’s proposed rule or laboratory regulations, please contact BMD Vice President and Healthcare Attorney Amanda Waesch.


Supreme Court Upholds Coverage under the Affordable Care Act

The U.S. Supreme Court has upheld the authority of the U.S. Preventive Services Task Force under the ACA, ensuring continued no-cost coverage for over 100 preventive health services. The decision impacts millions of Americans and preserves provider reimbursement through insurance.

Health Care Providers Take Note: Federal Budget Brings Medicaid and Staffing Rule Changes

The 2025 federal budget introduces significant changes for health care providers and Medicaid recipients, including new cost-sharing requirements, work eligibility mandates, rural health grants, and a pause on minimum staffing rules.

Key Healthcare Provisions in Ohio’s 2026–2027 Budget

Ohio’s newly enacted biennial budget (HB 96) for FY 2026–2027 brings sweeping changes for healthcare providers across the state. The law includes new Medicaid eligibility requirements, reporting mandates, funding directives, and social policy provisions. Several vetoes by Governor DeWine also affect healthcare-related initiatives.

Providers Beware: Court Sides with Insurers in No Surprises Act Arbitration

On June 12, 2025, the Fifth Circuit ruled in favor of Aetna and Kaiser in two lawsuits brought by air ambulance providers challenging how insurers calculated payments under the No Surprises Act’s Independent Dispute Resolution process. The court held that unless there is clear evidence of fraud or serious misconduct, IDR decisions will stand, reinforcing the finality of the arbitration process.

Introducing HB 281: Enforcement of Federal Immigration Laws in Ohio Hospitals

House Bill 281, introduced on May 20, 2025, would require Ohio hospitals to allow law enforcement, including federal immigration agents, to enter facilities and enforce immigration laws. The bill mandates that hospitals comply with information requests and adopt formal policies, raising significant concerns about patient privacy and access to care for immigrant communities.